Antibody targeting CD38 enzyme shows positive impact in treating systemic sclerosis
Based on the team's discovery that an enzyme called CD38, implicated in aging metabolism, is elevated in scleroderma and ...
Nature2 年
Ichnos aims to shift science with multispecific antibodies for immuno-oncology
The most advanced is ISB 1342, a first-generation bispecific antibody targeting both cluster of differentiation 38 (CD38) on myeloma cells and CD3 on T cells, which is in phase 1 testing for ...
pharmaphorum1 天
Biogen shows its IgAN hand with felzartamab data
Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...
Yahoo Finance1 个月
J&J’s Darzalex combination gains expanded label for multiple myeloma in Europe
The label expansion for the anti-CD38 antibody was supported by data from the ongoing Phase III PERSEUS trial that was submitted to to the European Medicines Agency in March 2024. Darzalex ...
The Pharma Letter6 天
Toward a functional cure: J&J's ambitions in multiple myeloma
Johnson & Johnson (J&J) has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies ...
Medpage Today on MSN2 天
Year in Review: Multiple Myeloma
One of the major stories in multiple myeloma in 2024 was the comeback of belantamab mafodotin (Blenrep) after it had been ...